Substituted imidazo[1,5-a]pyrazines and [1,2,4]triazolo[4,3-a]pyrazines for the modulation of AhR

A compound having formula Ib or formula Id:

• or a pharmaceutically acceptable salt thereof,
• wherein:
• X1 is C1-6 alkylene;
• Ar1 is a 5- to 9-membered heteroaryl, wherein the 5- to 9-membered heteroaryl contains at least one N heteroatom, and further wherein the 5- to 9-membered heteroaryl is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of deuterium, halogen, CN, C1-4 alkyl, C1-4 deuteroalkyl, C1-4 haloalkyl, C(O)Ra, C(O)NRaRb, C(O)ORa, NRaRb, NRbC(O)Ra, NRaC(O)NRaRb, NRbC(O)ORc, ORa, OC(O)Ra, OC(O)NRaRb, S(O)0-2Ra, and S(O)2NRaRb;
• Ar2 is phenyl or a 5- to 9-membered heteroaryl, wherein the phenyl is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of deuterium, halogen, CN, C1-4 alkyl, C1-4 deuteroalkyl, C1-4 haloalkyl, C(O)Rc, C(O)NRaRb, C(O)ORa, NRaRb, NRbC(O)Ra, NRaC(O)NRaRb, NRbC(O)ORc, ORa, OC(O)Ra, OC(O)NRaRb, S(O)0-2Ra, and S(O)2NRaRb, and further wherein the 5- to 9-membered heteroaryl is substituted with 0, 1, 2, or 3 substituents independently selected from the group consisting of deuterium, halogen, CN, C1-4 alkyl, C1-4 deuteroalkyl, C1-4 haloalkyl, C(O)Rc, C(O)NRaRb, C(O)ORa, NRaRb, NRbC(O)Ra, NRaC(O)NRaRb, NRbC(O)ORc, ORa, OC(O)Ra, OC(O)NRaRb, S(O)0-2Ra, and S(O)2NRaRb;
• R1 is C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C3-7 cycloalkyl, or C3-7 heterocycloalkyl;
• each Ra is independently H, C1-4 alkyl, or C1-4 haloalkyl;
• each Rb is independently H, C1-4 alkyl, or C1-4 haloalkyl;
• or
• each Ra and Rb, together with the N heteroatom to which they are attached, independently forms a 4- to 6-membered ring, wherein each 4- to 6-membered ring independently contains 0, 1, or 2 additional ring heteroatoms or ring heteroatomic groups independently selected from the group consisting of N, O, S, S(O), and S(O)2;
• and
• each Rc is independently C1-4 alkyl or C1-4 haloalkyl.